Studies of the interactions of antibodies with their Fc receptors, with a particular focus on the neonatal Fc receptor (FcRn) and its relationship with IgG and albumin. In addition, we are investigating how FcRn acts as a transporter in different cell types of the body. The studies will unravel the basic structural and cellular mechanisms that govern the functions of FcRn. Such knowledge offers opportunities for development of novel drug concepts that will secure improved half-life and biodistribution.
Studies of the mechanisms of infections at different body sites and how humoral immunity fights and restricts infection and virus replication. In particular, we are studying how antibodies contribute to protection against infectious diseases, and how FcRn and tripartite motif containing 21 (TRIM21) take part in cellular protection. Such knowledge can be utilized to develop novel antibody technologies tailored to combat infectious diseases.
Anthi AK, Kolderup A, Vaage EB, Bern M, Benjakul S, Tjärnhage E, Ruso-Julve F, Jensen KR, Lode HE, Vaysburd M, Nilsen J, Herigstad ML, Sakya SA, Tietze L, Pilati D, Nyquist-Andersen M, Dürkoop M, Gjølberg TT, Peng L, Foss S, Moe MC, Low BE, Wiles MV, Nemazee D, Jahnsen FLet al.(2025) An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models Nat Commun, 16(1), 3999 DOI 10.1038/s41467-025-59353-6, PubMed 40312392
Gelli HP, Vazquez-Uribe R, Buckley ST, Andersen JT, Alexander Sommer MO(2025) Advanced microbiome therapeutics for oral delivery of peptides and proteins: Advances, challenges, and opportunities Adv Drug Deliv Rev, 222, 115603(in press) DOI 10.1016/j.addr.2025.115603, PubMed 40349728
Gjølberg TT, Mester S, Calamera G, Telstad JS, Sandlie I, Andersen JT(2025) Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress BioDrugs, 39(3), 373-409 DOI 10.1007/s40259-025-00708-2, PubMed 40156757
